Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

RADNOR, Pa.--(BUSINESS WIRE)--Sep 10, 2024--

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.

A link to the event can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook,LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240910315715/en/

CONTACT: Investors

Sonya Weigle

Chief People and Investor Relations Officer

Marinus Pharmaceuticals, Inc.

sweigle@marinuspharma.comMedia

Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

mcameron@marinuspharma.com

KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH NEUROLOGY HEALTH PHARMACEUTICAL

SOURCE: Marinus Pharmaceuticals

Copyright Business Wire 2024.